Kamel Laribi

5.0k citations
62 papers · 1.2k · 1 hit paper · h-index 17

Impact in

  • Hematology top 2%
    • Multiple Myeloma Research and Treatments
    • Acute Myeloid Leukemia Research
  • Genetics top 5%
    • Chronic Lymphocytic Leukemia Research

Papers in

    • Acute Myeloid Leukemia Research 15
    • Multiple Myeloma Research and Treatments 12
    • Chronic Lymphocytic Leukemia Research 16
    • Myeloproliferative Neoplasms: Diagnosis and Treatment 8

Kamel Laribi

56 papers receiving 1.2k citations

Hit Papers

Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study 2018 · 307 citations
3070+2+5Years since publication100200300

Peers

Kamel Laribi
Comparison fields: 5 of 75
  • Hematology 604
  • Genetics 321
  • Oncology 606
  • Pathology and Forensic Medicine 329
  • Dermatology 140
Replace Ana Balanzategui with:
Ana Balanzategui Spain
Miguel Alcoceba Spain
Ángel León Spain
Kenton Wride United States
Maria‐Christina Kyrtsonis Greece
Katsumichi Fujimaki Japan
M. L. Vegna Italy
Pascale Lepelley France
Fernando Ramos Spain
Po Dunn Taiwan
Kamel Laribi relative to Ana Balanzategui Spain Ana Balanzategui's profile →
Citations per field
00.5×1.5×2.4×
Ana Balanzategui · 1×
Citations per year

Countries citing papers authored by Kamel Laribi

Since Specialization
Citations

This map shows the geographic impact of Kamel Laribi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kamel Laribi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kamel Laribi more than expected).

Fields of papers citing papers by Kamel Laribi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kamel Laribi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kamel Laribi. The network helps show where Kamel Laribi may publish in the future.

Co-authors

The 25 scholars most cited alongside Kamel Laribi, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Kamel Laribi Line = papers co-authored together Kamel Laribi links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 62 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study
Hit paper breakdown →
2018307
2 2016186
3 200167
4 201357
5 201850
6 201446
7 201845
8 202041
9 201637
10 201835
11 201631
12 201530
13 201721
14 201819
15 201217
16 202116
17 202116
18 201516
19 201515
20 201814

About Kamel Laribi

Kamel Laribi is a scholar working on Hematology, Genetics, Pathology and Forensic Medicine, Oncology and Molecular Biology, having authored 62 papers that have together received 1.2k indexed citations. Recurring topics across this work include Lymphoma Diagnosis and Treatment (22 papers), Chronic Lymphocytic Leukemia Research (16 papers), Acute Myeloid Leukemia Research (15 papers), Multiple Myeloma Research and Treatments (12 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (8 papers), CNS Lymphoma Diagnosis and Treatment (7 papers), Immunodeficiency and Autoimmune Disorders (6 papers) and Cutaneous lymphoproliferative disorders research (6 papers). The work is most often cited by research in Hematology (604 citations), Genetics (321 citations), Oncology (606 citations), Pathology and Forensic Medicine (329 citations) and Dermatology (140 citations). Kamel Laribi has collaborated with scholars based in France, United States and Spain. Frequent co-authors include Alix Baugier de Materre, Li Zhu, Kazuyuki Shimizu, Noopur Raje, Brian G.M. Durie, Wojciech Legieć, G. David Roodman, Evangelos Terpos, Douglas Warner and Wolfgang Willenbacher. Their work appears in journals such as Blood, British Journal of Haematology, Annals of Hematology, Journal of Clinical Oncology and European Journal Of Haematology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact